Online Stockmarket Trading Update

Viralytics Limited (VLA) is pleased to announce that it has received notice of a decision to grant a patent in Japan involving the use of Coxsackie A viruses including CAVATAKTM in the treatment of multiple myeloma. Japan is the world’s third largest pharmaceutical market behind the US and Europe, and multiple myeloma is an important blood cancer for which the patient prognosis is exceptionally poor, so the medical need is large. Specifically the patent covers the use of a pharmaceutical composition of any of the Coxsackieviruses A13, A15, A18, A20 and A21 in treating multiple myeloma. CAVATAKTM is Coxsackievirus A21.

Viralytics is listed on the Australian Stock Exchange (VLA), Viralytics’ principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology. CAVATAKTM is the trade name for Viralytics’ proprietary formulation of the Coxsackievirus Type A21 (CVA21). EVATAKTM is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1 (EV1). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of  cells, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion

www.viralytics.com

Viralytics Limited (VLA) is pleased to announce the granting of a patent by the United States Patent and Trademark Office covering a Coxsackie A virus capable of infecting cancer cells substantially in the absence of intercellular adhesion molecule-1 (ICAM-1).

Dr Darren Shafren, Viralytics Chief Scientific Officer said “CAVATAKTM targets and destroys cancerous cells following binding to surface expressed ICAM-1. The generation of this novel Coxsackie A virus, that can infect cancer cells in the absence of ICAM-1 expands the range of cancers that Viralytics panel of oncolytic viruses can potentially target”.

The scope of the allowed claims of Patent No. 8,114,416 covers a bio- selected form of Coxsackievirus A21 which was generated following passage in cells not expressing ICAM-1 but expressing decay accelerating factor  (DAF). Decay accelerating factor expression is up-regulated on the surface of many cancerous cells including ovarian, colorectal and gastric cancers,

making it a target for the newly bio-selected Coxsackievirus A21. Claims of the patent also cover specific changes induced on the surface of the Coxsackievirus A21 during the bio-selection process on DAF-expressing cancer cells that are believed to confer the extended scope of cancer cell targeting.

Viralytics’ principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology. CAVATAKTM is the trade name for Viralytics’ proprietary formulation of the Coxsackievirus Type A21 (CVA21). EVATAKTM is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1 (EV1). CVA21 and EV1 are viruses that occur naturally in the community. CVA21 and EV1 attach to the outside of cells, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). CVA21 uses the receptors, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF) to bind and infect target cells. Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others. EV1 uses the receptor, integrin α2β1 to bind and infect target cells. Integrin α2β1 has been demonstrated to be highly expressed on multiple cancer types, including: prostate cancer, ovarian cancer and others.

www.viralytics.com

http://www.traderdealer.com.au/fundamentals/vla